These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2533899)

  • 1. Safety of ondansetron.
    Smith RN
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S47-50; discussion S51-4. PubMed ID: 2533899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
    Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
    J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of serotonin antagonists for the control of chemotherapy-induced emesis.
    Hainsworth JD
    Semin Surg Oncol; 1993; 9(3):279-84. PubMed ID: 8516617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity and side effects of ondansetron.
    Finn AL
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):53-60. PubMed ID: 1387251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological and anti-emetic properties of ondansetron.
    Tyers MB; Bunce KT; Humphrey PP
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S15-9. PubMed ID: 2533894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical pharmacology of ondansetron.
    Blackwell CP; Harding SM
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S21-4; discussion S25-7. PubMed ID: 2533895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
    Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
    Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients.
    Hardy J; Daly S; McQuade B; Albertsson M; Chimontsi-Kypriou V; Stathopoulos P; Curtis P
    Support Care Cancer; 2002 Apr; 10(3):231-6. PubMed ID: 11904788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New, in Austria registered specialty drugs. Zofran (Ondansetron, Glaxo)].
    Erben M
    Wien Klin Wochenschr; 1991; 103(19):594-601. PubMed ID: 1836917
    [No Abstract]   [Full Text] [Related]  

  • 11. Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
    Early TE; Charbonneau J; McKnight G; Jenkins P
    J Post Anesth Nurs; 1995 Dec; 10(6):320-3. PubMed ID: 8632370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and severity of postoperative nausea and vomiting are similar after metoclopramide 20 mg and ondansetron 8 mg given by the end of laparoscopic cholecystectomies.
    Quaynor H; Raeder JC
    Acta Anaesthesiol Scand; 2002 Jan; 46(1):109-13. PubMed ID: 11903083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ondansetron, metoclopramide, and placebo in the prevention of postoperative emesis in children undergoing ophthalmic surgery.
    Bach-Styles T; Martin-Sheridan D; Hughes C; Kaufman S
    CRNA; 1997 Nov; 8(4):152-6. PubMed ID: 9437950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
    Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA
    Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.